Timber pharmaceuticals announces proposed public offering

Basking ridge, nj, nov. 02, 2021 (globe newswire) -- via newmediawire -- timber pharmaceuticals, inc. (“timber” or the “company”) (nyse american: tmbr), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock (or common stock equivalents). each share of common stock (or common stock equivalent) will be sold with a warrant to purchase one share of common stock. the company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. all of the shares of common stock (or common stock equivalents) and warrants to be sold in the offering are to be offered by timber. the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
TMBR Ratings Summary
TMBR Quant Ranking